IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS ESC Heart Failure Pub Date : 2025-02-04 DOI:10.1002/ehf2.15226
Solenn Fabien, Sandra Waechter, Gbenga A Kayode, Berno Müller, Marietta Roth, Friedrich Koehler
{"title":"Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review.","authors":"Solenn Fabien, Sandra Waechter, Gbenga A Kayode, Berno Müller, Marietta Roth, Friedrich Koehler","doi":"10.1002/ehf2.15226","DOIUrl":null,"url":null,"abstract":"<p><p>A limited number of studies with smartwatches (SWs) investigated their potential in the field of heart failure (HF). The aim of this scoping review is to understand the extent of current literature on SWs in the HF population and the device's potential to improve disease management. The literature search was performed on PubMed and Embase in March 2024. Inclusion criteria included the use of commercialized SWs, HF diagnosis and peer-reviewed publications. Articles were excluded if the SW was not the study intervention or was part of a broader intervention programme. Reviews, case reports and study protocols were excluded. Of 1200 identified articles, 13 were included in the scoping review, encompassing 1171 patients with HF, and findings were presented in a descriptive summary table. Validity of several SW-collected physiological metrics was assessed against established technologies. Heart rate and step count measures were deemed moderately accurate in the HF population with Fitbit trackers (n = 5 patients, r = 0.54) and Garmin watches [n = 15 patients (mean age: 65.5 ± 12.6 years), concordance correlation coefficient (CCC) = 0.89 for Vivofit 1 and CCC = 0.92 for Vivofit 3], respectively, while calorimetry was the least reliable measurement [n = 19 patients (mean age: 65.1 ± 6.6 years), mean difference to indirect calorimeter: P = 0.01 for Fitbit Charge 2, P = 0.02 for Mio Slice]. Wrist-worn activity trackers were positively received by patients with HF [91.3% of adherence in research setting (n = 70 patients, median age (IQR): 79 years (76-82)), and 64% in real-world environment (n = 14 patients)] and their health-care providers (six cardiologists out of six acknowledged the data's usefulness), although device ownership ranged from 10 to 50% among the HF population. Physical activity information collected from SWs was found to be valuable in assisting cardiologists with their New York Heart Association (NYHA) functional class assessment, which is known for its limited objectivity and reproducibility. Multiple studies found that SWs, especially Fitbit devices, successfully identified a pattern where the degree of exercise intolerance increased with higher NYHA classes. These findings suggested that activity trackers can objectively evaluate the severity of physical activity limitations. As the functional classification of patients influences treatment strategies, SWs could serve as a valuable tool to facilitate and optimize outpatient disease management. SWs could be used as a complement to standard monitoring in HF. With continuous technological advances, it will be valuable to follow the deployment of SWs and to investigate their contribution to increased patient safety and consequently to health care cost reductions.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15226","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

对智能手表(SW)在心力衰竭(HF)领域的潜力进行调查的研究数量有限。本范围综述旨在了解目前有关智能手表在心力衰竭人群中应用的文献范围,以及该设备在改善疾病管理方面的潜力。文献检索于 2024 年 3 月在 PubMed 和 Embase 上进行。纳入标准包括商业化 SW 的使用、HF 诊断和同行评议出版物。如果SW不是研究的干预措施或属于更广泛干预计划的一部分,则不纳入相关文章。综述、病例报告和研究方案也被排除在外。在确定的 1200 篇文章中,有 13 篇被纳入了范围界定审查,涉及 1171 名高血压患者,审查结果以描述性摘要表的形式呈现。根据已有技术对 SW 收集的几项生理指标的有效性进行了评估。在心房颤动人群中,Fitbit 追踪器(n = 5 名患者,r = 0.54)和 Garmin 手表[n = 15 名患者(平均年龄:65.5 ± 12.6 岁),Vivofit 1 的一致性相关系数 (CCC) = 0.89,Vivofit 3 的一致性相关系数 (CCC) = 0.92]的心率和步数测量被认为分别具有中等准确性,而热量测量是最不可靠的测量方法[n = 19 名患者(平均年龄:65.1 ± 6.6 岁),与间接热量计的平均差异:Fitbit = 0.01,r = 0.54]:Fitbit Charge 2 的 P = 0.01,Mio Slice 的 P = 0.02]。腕戴式活动追踪器受到了高血压患者及其医疗服务提供者(六位心脏病专家中有六位认可数据的实用性)的积极评价[在研究环境中,91.3%的患者坚持使用(n = 70 名患者,中位年龄(IQR):79 岁(76-82)),在真实环境中,64%的患者坚持使用(n = 14 名患者)],尽管高血压人群的设备拥有率从 10%到 50%不等。研究发现,从 SW 收集到的体力活动信息在协助心脏病专家进行纽约心脏协会 (NYHA) 功能分级评估方面很有价值,而该评估以客观性和可重复性有限而著称。多项研究发现,SW(尤其是 Fitbit 设备)能成功识别出一种模式,即随着 NYHA 分级的升高,运动不耐受的程度也随之升高。这些研究结果表明,活动追踪器可以客观地评估身体活动受限的严重程度。由于患者的功能分级会影响治疗策略,因此活动追踪器可以作为一种有价值的工具来促进和优化门诊病人的疾病管理。运动负荷传感器可作为高血压标准监测的补充。随着技术的不断进步,跟踪 SWs 的应用情况并研究其对提高患者安全以及降低医疗成本的贡献将是非常有价值的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review.

A limited number of studies with smartwatches (SWs) investigated their potential in the field of heart failure (HF). The aim of this scoping review is to understand the extent of current literature on SWs in the HF population and the device's potential to improve disease management. The literature search was performed on PubMed and Embase in March 2024. Inclusion criteria included the use of commercialized SWs, HF diagnosis and peer-reviewed publications. Articles were excluded if the SW was not the study intervention or was part of a broader intervention programme. Reviews, case reports and study protocols were excluded. Of 1200 identified articles, 13 were included in the scoping review, encompassing 1171 patients with HF, and findings were presented in a descriptive summary table. Validity of several SW-collected physiological metrics was assessed against established technologies. Heart rate and step count measures were deemed moderately accurate in the HF population with Fitbit trackers (n = 5 patients, r = 0.54) and Garmin watches [n = 15 patients (mean age: 65.5 ± 12.6 years), concordance correlation coefficient (CCC) = 0.89 for Vivofit 1 and CCC = 0.92 for Vivofit 3], respectively, while calorimetry was the least reliable measurement [n = 19 patients (mean age: 65.1 ± 6.6 years), mean difference to indirect calorimeter: P = 0.01 for Fitbit Charge 2, P = 0.02 for Mio Slice]. Wrist-worn activity trackers were positively received by patients with HF [91.3% of adherence in research setting (n = 70 patients, median age (IQR): 79 years (76-82)), and 64% in real-world environment (n = 14 patients)] and their health-care providers (six cardiologists out of six acknowledged the data's usefulness), although device ownership ranged from 10 to 50% among the HF population. Physical activity information collected from SWs was found to be valuable in assisting cardiologists with their New York Heart Association (NYHA) functional class assessment, which is known for its limited objectivity and reproducibility. Multiple studies found that SWs, especially Fitbit devices, successfully identified a pattern where the degree of exercise intolerance increased with higher NYHA classes. These findings suggested that activity trackers can objectively evaluate the severity of physical activity limitations. As the functional classification of patients influences treatment strategies, SWs could serve as a valuable tool to facilitate and optimize outpatient disease management. SWs could be used as a complement to standard monitoring in HF. With continuous technological advances, it will be valuable to follow the deployment of SWs and to investigate their contribution to increased patient safety and consequently to health care cost reductions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
期刊最新文献
Refractory heart failure due to acquired aortic coarctation after total arch replacement: find the right antidote! Delayed cardiac consequences unveiled by magnetic resonance imaging in a high-voltage electric shock survivor. Impact of immigration on outcomes following acute decompensated heart failure: A retrospective cohort study. Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis. Electron microscopic findings predict clinical outcomes in patients with non-ischaemic cardiomyopathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1